Any current/future new fundraising through debt or equity?

The transcript does not mention any current or planned fundraising through debt or equity. Alivus Life Sciences Limited remains a net debt-free company as of September 30, 2025. The company has cash and cash equivalents, including short-term investments, amounting to INR 653 crores. They have more than INR 650 crores of cash on hand and prefer to reinvest this cash back into the business for growth and capex needs. Capex projects are funded through internal accruals and better credit from suppliers, avoiding the need for external debt or equity raising at this time. The company is evaluating c

Any current/future capex/capital investment/strategic investment?

Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores. Board-approved capex budget for FY '26 is INR600 crores, including INR190 crores carryover from FY '25. Capex slowed in H1; R&D center spend is half the planned INR90-100 crores for FY '26, causing some delay. Planned capex spend for H2 FY '26 is around INR250 crores. Capacity expansion projects at Solapur, Ankleshwar, and Dahej are progressing well and on track. Ankleshwar projects to be operational by June 2026 (Q2 FY '27). Dahej projects expected operational from Q1 FY '27. Solapur facility targeted to start from April next year.

Future growth expectations in sales/revenue/volumes?

The company expects steady growth in FY '26, driven by strong demand momentum and improved visibility for the second half. Non-GPL business grew by ~40% driven by successful new product launches; outlook remains strong. Anticipated rebound in GPL business in the second half of FY '26. CDMO segment expected to show a meaningful turnaround in H2 FY '26 with five projects ramping up. Japan market to see new commercial launches, with 8-9 products going commercial, up from 4 previously, expecting 4 new molecules launched annually. Broad-based growth expected from emerging markets, LATAM, Japan, Eur

Future growth expectations in earnings/operating earnings/profits/EPS?

Alivus Life Sciences expects steady growth in FY '26 driven by strong demand momentum and improved visibility for the second half. High single-digit revenue growth is reaffirmed for FY '26, fueled by broad-based external sales growth, turnaround in GPL business, and ramp-up of CDMO projects. CDMO business is anticipated to rebound in the second half with new projects and existing project ramp-up. Profitability expected to sustain margins around 30% despite absence of PLI benefits, supported by new launches and operational efficiencies. EBITDA and PAT margins showed significant year-on-year imp

IN US

Sale is live|00:00:00left today

Alivus Life Sciences LtdQ3 FY25Pharmaceuticals & Biotechnology

Alivus Life Sciences Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,108P/E: 22.7Market Cap: ₹12.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 4

→The company expects steady growth in FY '26, driven by strong demand momentum and improved visibility for the second half.
→Non-GPL business grew by ~40% driven by successful new product launches; outlook remains strong.
→Anticipated rebound in GPL business in the second half of FY '26.
→CDMO segment expected to show a meaningful turnaround in H2 FY '26 with five projects ramping up.
→Japan market to see new commercial launches, with 8-9 products going commercial, up from 4 previously, expecting 4 new molecules launched annually.
→Broad-based growth expected from emerging markets, LATAM, Japan, Europe, and India.
→Overall capex and capacity expansions (Solapur, Ankleshwar, Dahej) on track to support growth.
→Guidance reaffirmed for high single-digit revenue growth in FY '26.

Margin guidance

Category 3

→Alivus Life Sciences expects steady growth in FY '26 driven by strong demand momentum and improved visibility for the second half.
→High single-digit revenue growth is reaffirmed for FY '26, fueled by broad-based external sales growth, turnaround in GPL business, and ramp-up of CDMO projects.
→CDMO business is anticipated to rebound in the second half with new projects and existing project ramp-up.
→Profitability expected to sustain margins around 30% despite absence of PLI benefits, supported by new launches and operational efficiencies.
→EBITDA and PAT margins showed significant year-on-year improvement, indicating profitability momentum.
→Working capital stable, with receivable days around 148 days, limited scope to significantly reduce working capital days.
→Capex spend reduced in H1 but projects remain on track to support growth.
→Pipeline strong with 586 DMF/CEP filings and 26 high-potent APIs under development.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript does not mention any current or planned fundraising through debt or equity.
→Alivus Life Sciences Limited remains a net debt-free company as of September 30, 2025.
→The company has cash and cash equivalents, including short-term investments, amounting to INR 653 crores.
→They have more than INR 650 crores of cash on hand and prefer to reinvest this cash back into the business for growth and capex needs.
→Capex projects are funded through internal accruals and better credit from suppliers, avoiding the need for external debt or equity raising at this time.
→The company is evaluating capital deployment opportunities but no specific plans for raising debt or equity were disclosed for the near term.

Order book

Yes

The transcript provided does not explicitly mention the current or expected order book or pending orders for Alivus Life Sciences Limited. However, some related insights are: - The CDMO business has a healthy pipeline with 586 DMF and CEP filings globally as of September 30, 2025. - There are 26 high-potent API products in the active development grid, representing a $66 billion addressable market. - The company is confident of a meaningful turnaround in the CDMO segment in H2 FY '26 due to new projects and ramp-up of existing projects. - The outlook for GPL business is positive with expected improvement in the second half of FY '26. - New product launches and a strong pipeline are driving growth expectations. - Capacities at Solapur, Ankleshwar, and Dahej are expanding to support business growth. No direct figures or detailed order backlog values are disclosed in the transcript.

Capex plans

Yes

→Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores.
→Board-approved capex budget for FY '26 is INR600 crores, including INR190 crores carryover from FY '25.
→Capex slowed in H1; R&D center spend is half the planned INR90-100 crores for FY '26, causing some delay.
→Planned capex spend for H2 FY '26 is around INR250 crores.
→Capacity expansion projects at Solapur, Ankleshwar, and Dahej are progressing well and on track.
→Ankleshwar projects to be operational by June 2026 (Q2 FY '27).
→Dahej projects expected operational from Q1 FY '27.
→Solapur facility targeted to start from April next year.
→Strategic focus on own R&D center with expandable space to support growth for next 5 years.
→Company holds INR650+ crores in cash; evaluating inorganic and other capital deployment opportunities but currently prioritizing organic growth.

How does Alivus Life Sciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Alivus Life Sciences Ltd

Rev 4Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Alivus Life Sciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio